Randomised, Double Blind, Placebo-controlled, Incomplete Block, 3-way Cross-over Study to Evaluate Efficacy and Safety of 4 Doses of Glycopyrronium Bromide (CHF5259) DPI in Moderate to Severe Patients With COPD

Trial Profile

Randomised, Double Blind, Placebo-controlled, Incomplete Block, 3-way Cross-over Study to Evaluate Efficacy and Safety of 4 Doses of Glycopyrronium Bromide (CHF5259) DPI in Moderate to Severe Patients With COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus First in man; Therapeutic Use
  • Acronyms GlycoNEXT
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 01 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top